Home »

RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression

GLEN ROCK, NJ — (Marketwired) — 12/15/16 — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression announces data for its CX1739 clinical study in opioid induced respiratory depression. Arnold Lippa, Ph.D., Executive Chairman and Chief Scientific Officer […]


© 2021 88Finance. All Rights Reserved. Log in

- Copyright by LayerMedia

Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de